Cost-effectiveness of<unk>  focuses on the use of balance of medical expenses and<unk> utic efficacy. In the case of GvHD<unk> , corticosteroids are the least expensive treatment option, and alternative immunosuppressants or biologics are more expensive.
Graft-versus-host disease cost-effectiveness of therapy
Multi-drug-resistant tuberculosis cost-effectiveness of therapy
Gangrene cost-effectiveness of therapy
Minimal change disease cost-effectiveness of therapy
Graft-versus-host disease future or investigational therapies
Trench mouth cost-effectiveness of therapy
Osteoporosis cost-effectiveness of therapy
Pneumoconiosis cost-effectiveness of therapy